More on AXSM
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $211.97 |
|
|||
| Open | $211.97 | ||||
| 52 Wk High | $15.74 | ||||
| 52 Wk Low | $5.37 | ||||
| Day High | $211.97 | ||||
| Day Low | $211.97 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 449 | ||||
- Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
- Axsome Therapeutics to Participate in Upcoming Investor Conferences
- Axsome begins Phase 3 trial of AXS-05 for smoking cessation
- Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
- H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
- Axsome Therapeutics (AXSM) PT Raised to $316 at Mizuho
- Axsome Therapeutics (AXSM) PT Raised to $251 at Morgan Stanley
- Axsome Therapeutics (AXSM) PT Lowered to $279 at RBC Capital
- Axsome Therapeutics (AXSM) PT Raised to $268 at Needham
- Axsome Therapeutics (AXSM) PT Raised to $256 at Wells Fargo
Entities mentioned with AXSM
- FDA | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Earnings | View Related Stories »
- PDUFA | View Related Stories »
- Definitive Agreement | View Related Stories »
- S1 | View Related Stories »
- Show More...
